---
title: Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid
  Cardiomyopathy
date: '2025-02-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39963776/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250218170842&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy,
  leading to heart failure across the spectrum of ejection fractions. Although there
  are approved disease-modulating therapies for the transthyretin subtype (transthyretin
  amyloid cardiomyopathy [ATTR-CM]), the role of heart failure medications remains
  uncertain and challenging in clinical practice. Their effects on clinical outcomes,
  such as mortality and hospitalization, are unknown for ATTR-CM. This review aims
  ...
disable_comments: true
---
Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy, leading to heart failure across the spectrum of ejection fractions. Although there are approved disease-modulating therapies for the transthyretin subtype (transthyretin amyloid cardiomyopathy [ATTR-CM]), the role of heart failure medications remains uncertain and challenging in clinical practice. Their effects on clinical outcomes, such as mortality and hospitalization, are unknown for ATTR-CM. This review aims ...